Acute promyelocytic leukemia

Slides:



Advertisements
Similar presentations
STATUS OF DETECTION OF MINIMAL
Advertisements

Molecular Haemato-Oncology at Bristol Genetics Laboratory
Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.
Susanna Akiki WMRGL 2009 Acute Promyelocytic Leukemia with t(15;17) (q22;q21) developing inv(16)(p13q22) secondary AML.
Who, What and When: Transplant for Acute Lymphoblastic Leukemia Brandon Hayes-Lattin September 13, 2013.
1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.
Novel Strategies for the Treatment of AML: Tailoring Treatment For Specific Genetic Subtypes Martin S. Tallman, M.D. Northwestern University Feinberg School.
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN.
Acute Promyelocytic Leukemia
Approach to Acute Leukemia
Acute Myeloid Leukaemia— phenotype and genotype
Hairy Cell Leukemia Foundation and
Retinoic Acid Receptor- Alpha and Its Role in Acute Promyelocytic Leukemia By Alex Sheng.
Retinoic Acid Receptor Alpha (RARα) Acute Promyelocytic Leukemia (APL)
Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.
Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.
Hematologic Malignancies
Fusion Genes in Cancer Wednesday, June 27th. Outline: Transcription Fusion genes Examples of fusion genes in cancer Summary and conclusions.
Molecular Medicine Dr Catherine Flynn Consultant Haematologist St James’s Hospital October 22 nd 2009.
Arsenic Trioxide (ATO) in the Consolidation Treatment of Newly Diagnosed APL — First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian.
Pei Lin, MD Department of Hematopathology UT M.D. Anderson Cancer Center, Houston, TX Monitoring of Minimal Residual Disease Principles and Applications.
Acute Promyelocytic Leukemia (APL)
Acute promyelocytic leukemia (APL) From the worst to the best prognosis MUDr. Petr Pavlíček Internal Hematological Clinics FNKV and 3LF UK in Prague.
영남대학교 의과대학 혈액종양내과 현 명 수 Curative Strategies in Acute Promyelocytic Leukemia.
Best of ASH 2007 Acute Leukemias Charles Linker MD #439Tipifarnib for elderly AML #593Combination arsenic & ATRA for APL #297NPM predicts ATRA response.
Retinoic Acid Receptor-α (RARα) & its role in Acute Promyelocytic Leukemia (APL) Danielle Matsushima.
Pre-Clinical Studies and Pharmacology of 13-Cis-Retinoic Acid in Neuroblastoma C. Patrick Reynolds, MD PhD Childrens Hospital Los Angeles University of.
SCIENCE MEETS MEDICINE: ACUTE PROMYELOCYTIC LEUKEMIA Nancy Fuller, M.D. June 23, 2004.
Blood Cancers in older adults Cancer and Older Adults 19 November 2015 Matthew Foster, MD Assistant Professor of Medicine Leukemia, Lymphoma and Myeloma.
Long-term Outcome after hyper-CVAD and Imatinib for De Novo or Minimally Treated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph-ALL)
Rationale for Developing New Drugs 25% of children with cancer will not survive 5 years25% of children with cancer will not survive 5 years The acute toxicity.
Single-Agent Lenalidomide Induces Complete Remission of Acute Myeloid Leukemia in Patients with Isolated Trisomy 13 Fehniger TA et al. Blood 2009;113(5):
AML NCCN guidelines 2009 Presented by CR 謝燿宇. Introduction Treatment of AML: age, hx of prior MDS or cytotoxic therapy and performance status The most.
TREATMENT. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
FDA ODAC AML in Older Individuals Frederick R. Appelbaum, MD May 5, 2005.
Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Are all APL screated equal? Background image removed due to copyright considerations.
Retinoic Acid Receptor α Acute Promyelocytic Leukemia Michi Nair.
Society for Hematopathology/ European Association for Haematopathology 2013 Workshop Case 145 Nidhi Aggarwal, M.D.; Robert L. Redner, MD; Fiona E. Craig,
Ashkan Emadi 1, Steven D. Gore Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, United States Blood Reviews 24 (2010)
Therapeutic Advances in Acute Myleoid Leukemia J Clin Oncol 29: (Volume 29. Number 5. February ) Samuel Aparicio, B.M., B.Ch., Ph.D., and.
Society for Hematopathology/ European Association for Haematopathology Case 211 Rachel Ochs, MD Adam Bagg, MD Hospital of the University of Pennsylvania.
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1   CC-486 (Oral.
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Acute Myeloid Leukemia
Clinical Focus: Acute Promyelocytic Leukemia
Platzbecker U et al. Proc ASH 2014;Abstract 12.
Early Molecular and Cytogenetic Response Predict for Better Outcomes in Untreated Patients with CML-CP — Comparison of 4 TKI Modalities (Standard- and.
by Elena A. Federzoni, Peter J. M. Valk, Bruce E
Monitoring and Management of Adult Relapsed/Refractory Acute Promyelocytic Leukemia.
Targeting FLT3 Mutations in Acute Myeloid Leukemia
The role of Minimal Residual Disease in
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Acute Myeloid Leukemia
Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.
Cancer Procoagulant and Tissue Factor Are Differently Modulated by All-trans-Retinoic Acid in Acute Promyelocytic Leukemia Cells by A. Falanga, R. Consonni,
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Volume 16, Issue 13, Pages (October 2015)
Diagnostic Hematology
Jonathan W. Friedberg M.D., M.M.Sc.
by David Grimwade, and Sylvie D. Freeman
Complete remission through blast cell differentiation inPLZF/RARα-positive acute promyelocytic leukemia: in vitro and in vivo studies by Maria C. Petti,
Grövdal M et al. Blood 2008;112:Abstract 223.
Updates in the Management of Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data  Preetesh Jain, Hagop Kantarjian,
Neoplastic disorder.
Preclinical trials in mouse models of APL
How I treat T-cell acute lymphoblastic leukemia in adults
Presentation transcript:

Acute promyelocytic leukemia Severe coagulopathy Striking sensitivity to anthracyclines TAILORED DIAGNOSIS AND MANAGEMENT Response to differentiating agents (RA, ATO) Specific genetic lesion

M2 M1 M5 M3

PML locus RAR locus 15 17 PML/RAR fusion gene RAR/PML fusion gene 15q+ 17q-

PML/RAR Pharmacologic doses Co-repressor (10-6 M) RAR Co-activators NCor HDAC Sin3 Pharmacologic doses (10-6 M) Co-repressor NCor HDAC Sin3 RAR Co-activators (HAT) RA RARE PML transcriptional activation Represión

RT-PCR amplification of the PML/RAR hybrid 3 4 5 6 3 bcr 1 3 4 5 6 3 bcr 2 3 3 bcr 3

PML/RARa as Ideal Marker for Disease Diagnosis and Monitoring Causally related to disease pathogenesis Targeted by specific therapy Predicts response to retinoids

Clinical relevance of genetic studies in APL Diagnosis Response to front-line therapy Follow-up monitoring and therapy of molecular relapse

PML/RARa predicts response to R.A. Miller et al, PNAS 1992 N. cases Cytogenetics PML/RARa R.A. response 24 24 +ve 24 +ve 100% 4 4 not evaluable 4 +ve 100% 4 +ve 100% 8 8 normal 4 -ve 0%

PCR-monitoring studies in large clinical trials GIMEMA MRC PETHEMA AMLCG MDACC US Intergroup MSKCC JALSG

PCR-Adapted Therapy in APL PML-RARa neg. RA + CHT Induction RA + CHT Consolidation PML-RARa pos. (sensitivity 10-4) Maintenance DIAGNOSIS Further intensification Salvage Rx

MILESTONES IN APL THERAPY 1972 Exquisite sensitivity to anthracyclines 1987 Differentiative response to RA 1993 RA + CHT > CHT 93-99 Optimization of RA +CHT combination 97-99 ATO, other RA derivatives 2000 Anti-CD33, HDAC inhibitors

APL AS A MODEL FOR TARGETED Rx RA + anthracycline CHT Arsenic & other RA derivatives Anti-CD33 MoAbs HDAC inhibitors FLT3 inhibitors

TARGETED TREATMENT OF APL RA + anthracycline CHT Arsenic & other RA derivatives Anti-CD33 MoAbs HDAC inhibitors FLT3 inhibitors

Acute Promyelocytic Leukemia + RA

Disease-Free Survival AIDA 0493 vs AIDA 2000 (all risks) 1 AIDA2000: 86% (CI 95%: 80 - 92) .75 AIDA0493: 72% (CI 95%: 66 - 78) .50 .25 p=0.09 The actuarial event-free survival is 73% at 5 years for the LPA96, and 85% at two years for the LPA99. 1 2 3 4 5 6 7 years

TARGETED TREATMENT OF APL RA + anthracycline CHT Arsenic & other RA derivatives Anti-CD33 MoAbs HDAC inhibitors FLT3 inhibitors

Dual response of APL cells to arsenic trioxide

US Multicenter trial with A2O3 Molecular Response by Cycle PCR Response n=45

Molecular remission as a therapeutic goal in APL - Molecular remission in PML-RARa positive APL by combined ATRA and idarubicin. Mandelli et al 1997 - Presenting WBC count and kinetics of molecular remission predict prognosis in APL treated with ATRA. Burnett et al. 1999 - Molecular remission by liposomal encapsulated ATRA in newly diagnosed APL. Estey et al. 1999 - Molecular remission induction with ATRA and anti-CD33 MoAb HuM195 in APL. Jurcic et al. 2000

US Multicenter trial with As2O3 for relapsed APL 6 12 18 24 30 36 Months 0% 20% 40% 60% 80% 100% 18-Month OS estimate: 66% Median Follow-up: 18.3 months

TARGETED TREATMENT OF APL RA + anthracycline CHT Arsenic & other RA derivatives Anti-CD33 MoAbs HDAC inhibitors FLT3 inhibitors

RATIONALE FOR MYLOTARG IN APL - Homogeneous CD33 staining in 100% cases - Striking sensitivity to anthracyclines - Absent / minimal gp170 (MDR) expression

ATRA (A) + Mylotarg (M) Trial In Untreated APL (MD Aderson) Induction ATRA until CR M 9 mg/m2 d 5 (d 1 if WBC >10) Ida 12 mg/m2 d1-3 (if WBC > 30) In CR ATRA 2 weeks on/2 weeks off M 9 mg/m2 Q 4-5 weeks (X 8) Ida 12 mg/m2 X 3 only if PCR +

MYLOTARG FOR MOLECULAR RELAPSE (Gimema) Dose 1* Dose 2* PCR PCR+ve PCR-ve Dose 3* and successive doses until PCR-negativity (max 3 further doses) Dose 3* ( final dose) * 6mg/m2 i.v.

Mylotarg for molecular relapse (GIMEMA) Mos from Pts Pts My doses Tested PCR Negative After 2nd 8 8 After 3rd 6 6 4-6 m 4 2 8-10 m 2 2 12-14 m 2 2

Mylotarg per la recidiva molecolare Sopravvivenza globale (N=16) 74% ± 14% Lo Coco, Blood 2004

TARGETED TREATMENT OF APL RA + anthracycline CHT Arsenic & other RA derivatives Anti-CD33 MoAbs HDAC inhibitors FLT3 inhibitors

PLZF/RAR Pharmacologic doses Co-repressor (10-6 M) RAR Co-activators NCor HDAC Sin3 Pharmacologic doses (10-6 M) Co-repressor Differentiation induction NCor HDAC Sin3 RAR Co-activators (HAT) RA RARE PLZF HDAC Sin3 NCor TSA

Transcriptional therapy with HDAC inhibitors

TARGETED TREATMENT OF APL RA + anthracycline CHT Arsenic & other RA derivatives Anti-CD33 MoAbs HDAC inhibitors FLT3 inhibitors

= Ig-like = TM = JM = TK P P P P = FL P STAT JAK RAS MAD

FINDING THE NEXT GLEEVEC: FLT3 TARGETED KINASE INHIBITOR THERAPY FOR AML Sawyers, Cancer Cell 2002

Survival of FLT3-ITD+ mice treated with/wo (P) PKC412 0.8 0.6 0.4 0.2 P P=0.0005 0 20 40 60 80 100 d. Weisberg, Cancer cell 2002

Combined Modality Therapy for APL (MSKCC) Differentiation Therapy All-Trans Retinoic Acid Immunotherapy HuM195 Arsenic Trioxide Transcription Modulation Chemotherapy Idarubicin RT-PCR* *Adaptive Regulation: Number of idarubicin courses determined by RT-PCR results.

Type I lesions (point mutations) Type II lesions (fusion genes) prolif./survival advantage differentiation block APL (AML) Transcriptional targeting (ATRA, ATO, HDAC inhib.) Targeting prolif. (e.g. FLT3 inhib.)

ACKNOWLEDGMENTS Daniela Diverio Miguel A. Sanz David Grimwade Andrea Biondi Pascual Bolufer Alan K. Burnett Pier G. Pelicci Guillermo Martin Antony Goldstone Franco Mandelli Eva Barragan GIMEMA (Italy) PETHEMA (Spain) MRC (UK) Steve Soignet Elihu Estey David Scheinberg Hagop Kantarjian MSKCC, NY MDACC, Houston